Anti-depressant effect of cerebrolysin in reserpine-induced depression in rats: Behavioral, biochemical, molecular and immunohistochemical evidence

Chem Biol Interact. 2021 Jan 25:334:109329. doi: 10.1016/j.cbi.2020.109329. Epub 2020 Dec 3.

Abstract

Depression is a major psychological disorder that contributes to global health problem. This study aimed to evaluate the anti-depressant effect of Cerebrolysin (CBL) in Reserpine-induced depressed rats, its effect on oxidative stress, inflammation, regulatory cyclic AMP-dependent response element binding protein (CREB)/brain derived neurotropic factor (BDNF) signaling pathways, brain monoamines and histopathological changes was assessed. Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days. The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection. Then analyses were conducted. CBL reversed Reserpine-induced reduction in latency to immobility and prolongation of immobility time in the forced swimming test (FST), reduced malondialdehyde (MDA), elevated reduced glutathione (GSH), reduced tumor necrosis factor-alpha (TNF-ɑ), and elevated BDNF cortical and hippocampal brain contents. CBL elevated protein kinase A (PKA) and nuclear factor kappa-B (NF-κB) cortical and hippocampal protein expressions. CBL also ameliorated alterations in mRNA expressions of protein kinase B (AKT), CREB and BDNF in the cortical and hippocampal tissues. CBL elevated nor-epinephrine (NE), serotonin (5-HT), and dopamine (DA) and reduced 5-Hydroxyindoleacetic acid (5-HTAA), 3,4-Dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) cortical and hippocampal contents. CBL effects were in parallel to those observed with the standard anti-depressant drug, FLU. This study shows that CBL exerted anti-depressant effect evidenced by attenuation of oxidative stress and inflammation as well as enhancement of neurogenesis, amelioration of monoaminergic system and histopathological changes.

Keywords: Anti-depressant; Brain monoamines; Cerebrolyin; Inflammation; Regulatory CREB/BDNF signaling Pathway; Reserpine.

MeSH terms

  • Amino Acids / pharmacology*
  • Animals
  • Antidepressive Agents / pharmacology*
  • Brain-Derived Neurotrophic Factor / metabolism
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / metabolism
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Depression / drug therapy*
  • Depression / metabolism
  • Disease Models, Animal
  • Dopamine / metabolism
  • Fluoxetine / pharmacology
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Inflammation / metabolism
  • Male
  • NF-kappa B / metabolism
  • Neurogenesis / drug effects
  • Oxidative Stress / drug effects
  • Proto-Oncogene Proteins c-akt / metabolism
  • Rats
  • Rats, Wistar
  • Reserpine / pharmacology*
  • Serotonin / metabolism
  • Signal Transduction / drug effects

Substances

  • Amino Acids
  • Antidepressive Agents
  • Brain-Derived Neurotrophic Factor
  • Cyclic AMP Response Element-Binding Protein
  • NF-kappa B
  • Fluoxetine
  • Serotonin
  • cerebrolysin
  • Reserpine
  • Proto-Oncogene Proteins c-akt
  • Dopamine